Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Renal Corticomedullary Abscess : Article by

Quick Find
Authors & Editors
Introduction
Indications
Relevant Anatomy
Contraindications
Workup
Treatment
Complications
Outcome And Prognosis
Future And Controversies
Multimedia
References




Patient Education
Infections Center

Kidneys and Urinary System Center

Urinary Tract Infections Overview

Urinary Tract Infection Causes

Urinary Tract Infection Symptoms

Urinary Tract Infections Treatment

Antibiotics Introduction




Author: T Brian Willard, MD, Consulting Staff, Department of Surgery, Division of Urology, Lexington Urological Associates

T Brian Willard is a member of the following medical societies: American Urological Association

Coauthor(s): J Lynn Teague, MD, FACS, FAAP, Clinical Assistant Professor, Department of Surgery, Division of Urology, University of Missouri at Columbia; Keith Steinbecker, MD, Consulting Staff, Department of Urology, St John's Mercy Medical Center

Editors: Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Shlomo Raz, MD, Professor, Department of Surgery, Division of Urology, University of California at Los Angeles School of Medicine; J Stuart Wolf, Jr, MD, FACS, David A Bloom Professor of Urology, Director, Division of Minimally Invasive Urology, Department of Urology, University of Michigan Medical Center; Stephen W Leslie, MD, FACS, Founder and Medical Director of the Lorain Kidney Stone Research Center, Clinical Assistant Professor, Department of Urology, Medical College of Ohio

Author and Editor Disclosure

Synonyms and related keywords: renal corticomedullary abscess, intrarenal abscess, acute focal bacterial nephritis, lobar nephronia, focal pyelonephritis, acute multifocal bacterial nephritis, emphysematous pyelonephritis, xanthogranulomatous pyelonephritis, XGP, kidney infections, perirenal space infections, intrarenal inflammatory processes, intra-renal inflammatory processes, diabetes mellitus, enteric gram-negative bacteria, enteric gram-negative bacilli, renal corticomedullary infections, renal inflammatory disease, recurrent urinary tract infections, renal calculi, diabetic cystopathy, vesicoureteral reflux, Proteus species, Pseudomonas species, Klebsiella species, Enterobacter species, Streptococcus faecalis, S faecalis, Staphylococcus aureus, S aureus, Proteus mirabilis, P mirabilis, Escherichia coli, E coli

Kidney and perirenal space infections are uncommon. However, when present, they can exact a significant degree of morbidity and mortality. Renal corticomedullary abscess is a spectrum of disease encompassing various intrarenal inflammatory processes. These processes include acute focal bacterial nephritis (eg, lobar nephronia, focal pyelonephritis), acute multifocal bacterial nephritis, emphysematous pyelonephritis, and xanthogranulomatous pyelonephritis (XGP). Renal corticomedullary abscess differs from renal cortical abscess (ie, renal carbuncle) because it develops from ascending rather than hematogenous spread of bacteria.

History of the Procedure

Development of a corticomedullary abscess is usually associated with an underlying urinary tract abnormality (eg, vesicoureteral reflux [VUR], urinary tract obstruction). It most commonly occurs in patients with diabetes mellitus with or without urinary tract obstruction. The following history is suggestive of the diagnosis:

  • Recurrent urinary tract infections
  • Renal calculi
  • Prior genitourinary instrumentation
  • VUR in children
  • Diabetic cystopathy
  • Xanthogranulomatous pyelonephritis

Problem

Recurrent urinary tract infections

Enteric gram-negative bacteria are the usual infecting organisms among all age groups. Approximately 66% of patients have a history of recurrent urinary tract infections. Bacterial pathogens causing cystitis ascend to the upper tract to infect the renal medulla. Subsequent liquefaction of the renal parenchyma and eventual involvement of the renal cortex is the postulated pathogenesis for the development of corticomedullary abscess. Scarring of the ureters and the ureteral pelvic junction also may occur, causing obstructive symptoms.

Renal calculi

Nephrolithiasis is present in approximately 30% of patients with corticomedullary abscess. These patients often have associated bladder infections that may result in bacterial seeding of the renal calculi. Furthermore, the presence of renal calculi may result in tubular scarring. Struvite stones (magnesium-ammonium-phosphate) are produced by urea-splitting bacteria such as Proteus, Pseudomonas, and Klebsiella species.

Genitourinary instrumentation

Urologic procedures such as ureteroscopy or endopyelotomy may cause ureteral trauma resulting in ureteral stricture and obstruction. Approximately two thirds of patients with corticomedullary abscess have a history of prior urinary instrumentation.

Vesicoureteral reflux

Normal human anatomy dictates that the ureterovesical junction (UVJ) should allow urine to enter the bladder but prevent urine from refluxing back into the kidney. Thus, the kidney is protected from contamination by infected urine. When the UVJ is incompetent, the risk of ascending urinary tract infections increases. The major cause of VUR is weak detrusor backing in combination with a short intramural tunnel. Primary causes of VUR include congenital trigonal weakness or complete ureteral duplication with refluxing lower pole moiety. Secondary causes of reflux include poorly compliant neurogenic bladder or infravesical obstruction resulting in a high-pressure bladder. Refluxing infected urine increases the risk of reflux nephropathy, hypertension, pyelonephritis, and corticomedullary abscess.

Diabetes mellitus

More than 50% of patients with corticomedullary abscess have diabetes mellitus. Factors that predispose patients with diabetes mellitus to intrarenal abscess include diabetic neuropathy, diabetic cystopathy, and impaired leukocyte function.

Diabetes mellitus causes sensory paralytic bladder followed by motor paralytic bladder. This occurs as a result of ischemic damage to the sensory and motor fibers innervating the detrusor muscle. Initially, an areflexic bladder has a normal compliance with low intravesical pressure. However, over time, the detrusor undergoes fibrosis and becomes poorly compliant with high intravesical pressure. This high intravesical pressure is transmitted to the renal parenchyma, and reflux nephropathy results. In the setting of bacterial cystitis, reflux of infected urine may result in parenchymal infection and renal scarring. An impaired immune system may increase the incidence of recurrent urinary tract infections and abscess formation.

Frequency

Pyelonephritis that subsequently leads to corticomedullary abscess is rare. Incidence of these suppurative intrarenal infections ranges from 1-10 cases per 10,000 hospital admissions. Both males and females are affected, with approximately equal frequency. However, renal cortical abscesses are 3 times more common in males. XGP, by contrast, is more common in females. Prevalence of XGP is exceedingly rare and accounts for less than 1% of renal inflammatory cases. Although it can occur at any age, XGP is more common in patients who are older, typically in the fifth to seventh decades of life.

Etiology

Renal corticomedullary abscess is caused by enteric gram-negative bacilli often coupled with urinary tract abnormalities. Escherichia coli is responsible for 75% of infections. Approximately 15-20% of cases are caused by Klebsiella, Proteus, Enterobacter, and Serratia species. The remaining small percentage of infections is divided among gram-positive bacteria, including Streptococcus faecalis and, less commonly, Staphylococcus aureus.

Pathophysiology

Renal cortical abscess results from hematogenous spread of bacteria from a primary focus of infection outside the kidney. The source is no longer apparent in up to one third of cases at the time of diagnosis. S aureus is the etiologic agent in 90% of cortical abscess cases. In contrast, renal corticomedullary abscess develops as an ascending infection by organisms already isolated within the urinary tract. Severe renal parenchymal involvement observed with corticomedullary abscess is more likely to extend to the renal capsule and perforate, thus forming a perinephric abscess. Several acute and chronic inflammatory processes are designated as renal corticomedullary infections.

Acute focal bacterial nephritis

Acute focal bacterial nephritis (eg, lobar nephronia, focal pyelonephritis) is a well-localized inflammation of the kidney without frank abscess formation. It is a form of bacterial interstitial nephritis that usually causes interstitial inflammation within a focal area of the kidney. Histologic characteristics include marked infiltration with polymorphonuclear leukocytes at the apex of the medulla with distortion of the glomeruli and renal tubules. In many patients, infection may represent an early phase that progresses to the more severe acute multifocal bacterial nephritis. With this entity, a heavy polymorphonuclear infiltrate is present throughout the kidney with areas of liquefaction and abscess formation.

Emphysematous pyelonephritis

Emphysematous pyelonephritis is an uncommon but severe necrotizing form of acute multifocal bacterial nephritis. Abdominal radiography (ie, kidneys, ureter, bladder [KUB]) exhibits characteristic intraparenchymal gas. The gas is within the renal parenchyma, not within the collecting system. The presence of gas suggests the presence of gas-forming anaerobic or facultative anaerobic pathogens. The gas is produced by bacterial fermentation of glucose in the necrotic infected tissue. Although E coli is the most common organism associated with this disease, any lactose-fermenting organism may be involved. Diabetes mellitus is the most common risk factor associated with emphysematous pyelonephritis, carrying an overall mortality rate of approximately 45%.

Xanthogranulomatous pyelonephritis

XGP is a chronic long-term infection of a renal unit often associated with a renal calculus. As a result of long-standing infection, the kidney enlarges and fixes itself to the retroperitoneum by perirenal fibrosis and extension of the granulomatous inflammation. Native tissue planes, such as the plane between Gerota fascia, adjacent retroperitoneal structures, and the peritoneum, are disrupted. Histologically, granulomatous tissue that contains lipid-laden macrophages (ie, foam cells) destroys and replaces the renal parenchyma. Renal calculi are usually present with XGP (75% of patients), and approximately 50% of those are staghorn calculi. Proteus mirabilis is the most common bacteria associated with XGP, but E coli is also common. A pathologic classification system stratifies the disease into the following 3 stages according to the amount of renal and perirenal involvement:

  • Stage I (nephritic): Characteristic xanthogranulomatous infection occurs in the kidney.
  • Stage II (perinephric involvement): This stage includes renal parenchyma and Gerota fascia.
  • Stage III (paranephric): Widespread extension into the retroperitoneum occurs.

XGP is known as the great imitator because of its clinical, radiologic, and pathologic similarities to renal tumors. Association of XGP with renal cell carcinoma, transitional cell carcinoma, and squamous cell carcinoma has been described.

Clinical

Clinical features that are typically present in patients with corticomedullary abscess include fever, chills, and flank or abdominal pain. Dysuria and other urinary tract symptoms are variably present. Nonspecific constitutional symptoms (eg, malaise, fatigue, weight loss) may manifest in patients with a chronic process, especially those with XGP.

Medical history

Medical history is extremely important when evaluating patients suspected of having a renal process consistent with corticomedullary abscess. Several host factors influence the development and severity of renal infection. Most patients have a history of recurrent urinary tract infections, renal calculi, and/or prior genitourinary tract instrumentation. A history of urinary tract obstruction is an important predisposing factor. Most patients report flank or abdominal pain. Associated gastrointestinal symptoms, such as nausea and vomiting, are also common.

Physical examination

Signs of renal abscess vary greatly and have no specific characteristics to aid in making the diagnosis. However, begin with evaluation of vital signs and general appearance. Most patients with renal infection appear ill and in distress. They often are febrile and may demonstrate signs of hemodynamic instability. Some may be tachycardic and hypotensive, manifesting the clinical picture of sepsis. Although palpable masses are not consistent findings, they are often encountered. A flank mass is present in 70% of patients with XGP. Costovertebral angle tenderness is almost uniformly present with each type of corticomedullary infection.

Basic laboratory data are variable. However, most patients demonstrate a leukocytosis with a left shift on CBC and differential. Urine and blood culture results are often positive. Urinalysis also shows signs of infection; however, bacteruria and pyuria may be absent if the ureter is completely obstructed.



Indications to intervene aggressively include persistent infection unresponsive to appropriate antibiotics, impending sepsis, and ongoing hemodynamic instability.



The kidneys lie along the borders of the psoas muscle and are placed obliquely. The right kidney is lower than the left kidney because of the overlying liver. The kidneys demonstrate mobility with inspiration and expiration. Lack of mobility suggests abnormal fixation, which often occurs with either acute inflammatory processes (eg, acute pyelonephritis) or chronic fibrosing processes such as xanthogranulomatous pyelonephritis (XGP).

The kidney is composed of an outer cortex, central medulla, internal calices, and pelvis. The cortex is homogenous in appearance. The medulla consists of numerous pyramids formed by converging collecting renal tubules, which drain into minor calices. The minor calices unite to form 2 or 3 major calices, which join to form the renal pelvis. Renal calices (most often at the upper and lower poles) affected by the intrarenal reflux of infected urine may result in corticomedullary abscess formation.

The ureter courses from the renal pelvis to the posterolateral aspect of the bladder. Areas of relative narrowing occur at the ureteropelvic junction (UPJ), where the ureter crosses over the iliac vessels, and at the UVJ. These are sites where a ureteral calculus is likely to become obstructed. The relative incidence of ureteral obstruction is as follows: UVJ is greater than UPJ, which is greater than crossing of the iliacs.

The nephron is the functioning unit of the kidney. It is composed of the glomerulus, proximal convoluted tubule, descending and ascending limbs of the loop of Henle, distal convoluted tubule, and collecting duct.

The renal arteries carry approximately 20% of the entire cardiac output, and of this, approximately 90% is filtered by the glomeruli in the renal cortex.

The blood supply to the kidney arises from a single renal artery and leads to multiple branching end arteries. These are without collateral circulation. Therefore, occlusion of any of these vessels produces infarction of the affected renal segment. Infarction of the entire kidney occurs if the main renal artery is occluded.

Usually, one renal artery arising from the aorta enters the renal hilum. At the renal hilum, the renal artery divides into anterior and posterior segmental branches. The posterior branch supplies a large portion of the posterior segment of the kidney. The anterior branch further divides to supply the upper and lower poles and the entire anterior surface of the kidney. Segmental arteries divide into interlobar arteries that ascend between the renal pyramids. At the corticomedullary junction, interlobar arteries branch into arcuate arteries that course along the base of the pyramids, parallel to the surface of the kidney. Arcuate arteries give rise to the interlobular arteries that run into the renal cortex and divide into the afferent glomerular arterioles of the glomerulus. Filtration occurs within the glomerulus. Efferent glomerular arterioles leave the glomerulus to descend as vasa recta to supply the renal medulla.

An intrarenal abscess occurs within the renal capsule. Untreated and fulminant infections can rupture through the capsule and involve the perinephric space as well as the retroperitoneum. Because the kidneys are positioned retroperitoneally, 3 areas are of considerable importance when discussing infections in this area:

  • Anterior perirenal space - Contains portions of the pancreas, bowel, and colon
  • Perinephric space - Contains Gerota fascia and the adrenals
  • Intrarenal space - Contains renal parenchymal tissue

Spread of infection can adversely impact these vital structures. Once infection spreads to the perinephric spaces, percutaneous or open surgical drainage is required. Identifying and treating an intrarenal abscess before capsular invasion occurs can prevent perinephric and retroperitoneal spread of infection to avoid further complications.



Contraindications regarding medical therapy deal primarily with adverse reactions to antibiotics. If a patient has a known hypersensitivity or allergy to a medication, an alternative should be used. A coagulopathy is the main contraindication to percutaneous drainage or surgical intervention. In most cases, the coagulopathy can be corrected so that the appropriate therapy can be delivered.



Lab Studies

  • Obtain CBC count with differential to demonstrate elevated peripheral leukocytosis with a left shift. Anemia may be present in patients with xanthogranulomatous pyelonephritis (XGP).
  • Conduct an electrolyte analysis.
    • BUN and creatinine levels are often elevated. This is usually caused by prerenal azotemia. Hypovolemic states occur secondary to vomiting with GI fluid loss or decreased renal perfusion, which is observed in septic shock. Patients who develop acute renal failure, as demonstrated by rising BUN and creatinine levels, show altered renal resorptive capabilities.
    • Calculate fractional excretion of sodium (FENa) and measure urinary electrolyte levels to aid in diagnosis.
      • FENa (%) = (UNa X Pcr)/(PNa X UCRE) X 100
        UNa = urinary sodium
        Pcr = plasma creatine
        PNa = plasma sodium
        UCRE = urine creatinine
    • Calculated FENa is less than 1% in prerenal azotemia. If FENa is greater than 1%, acute tubular necrosis is more likely.
  • Findings on urinalysis are typically abnormal in patients with corticomedullary abscess. Pyuria and proteinuria are common.
  • Although often positive, urine culture may fail to grow a causative organism. Patients with emphysematous pyelonephritis and XGP have positive urine cultures approximately 75% of the time. The most common pathogens recovered in affected patients are E coli, P mirabilis, and Klebsiella species.
  • Blood cultures are positive in more than 50% of patients and are particularly useful in patients with urosepsis. The isolated organisms are usually the same gram-negative microbes isolated from the patient's urine.

Imaging Studies

  • Many imaging modalities are available to clinicians, each with certain advantages and disadvantages. Renal ultrasonography and CT scanning are the fundamental tests for diagnosing corticomedullary abscesses. CT scanning is, by far, the study of choice in evaluating intrarenal abscesses. Ultrasonographic findings are less specific than findings on CT scanning, and MRI usually offers no additional information compared to CT scanning.
  • KUB radiography often is not helpful in identifying intrarenal abscess; however, it may show radio-opaque stones in the case of calculus-induced obstruction or intraparenchymal gas in patients with emphysematous pyelonephritis.
  • Intravenous pyelography limits the characterization of acute renal parenchymal infections. Studies that compare renal sonography with intravenous urography in the setting of acute renal infection demonstrate that ultrasonography in combination with plain abdominal radiography may be as helpful in detecting urologic abnormalities as intravenous urography.
  • Renal ultrasonography is a rapid and relatively inexpensive initial screening tool that detects renal lesions and anatomic abnormalities. The presence of an ill-defined renal mass with low-amplitude internal echoes and disruption of the corticomedullary junction is suggestive of an intrarenal abscess.
  • If the index of suspicion for a renal abscess is high, obtain a CT scan, even if ultrasonography is unrevealing.
    • Noncontrast CT scanning is a poor study for demonstrating intrarenal abscesses. When a CT scan is obtained in a clinical situation and a renal abscess is suspected, obtain both contrast and noncontrast images for comparison purposes. CT scanning is extremely useful to aid in characterizing renal infections as diffuse or focal, to detect the presence of gas, and to help the clinician determine whether perinephric extension exists.
    • CT scanning typically shows a poorly defined, wedge-shaped, hypodense area that may involve liquefaction. Focal renal involvement is common.
    • Search for the characteristic appearance of corticomedullary abscess, which is a low-attenuation (0-20 Hounsfield U), distinctly marginated, parenchymal lesion that fails to enhance after contrast administration.
    • CT scanning is the most useful modality in diagnosing intrarenal abscess and in planning operative procedures for treatment.



Medical therapy

Treatment of acute focal and multifocal pyelonephritis with appropriate antibiotics should produce a clinical response within 1 week of initiating therapy in most patients. However, well-established large abscesses are often difficult to treat with antibiotics alone.

In most patients, attempt an intensive trial of appropriate antibiotics directed against culture-specific bacteria before attempting surgical drainage.

If corticomedullary abscess is suspected, promptly administer parenteral antibiotics and intravenous hydration.

Consider administering a penicillin derivative, a cephalosporin, an aminoglycoside, or a fluoroquinolone.

If choosing a combination therapy, use a beta-lactam antibiotic administered intravenously with an aminoglycoside. Administer this line of therapy until culture and sensitivity results are received and then modify the antimicrobial therapy to the most appropriate agent.

Drug Category: Antibiotics -- Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

Drug NamePiperacillin and tazobactam sodium (Zosyn) -- Antipseudomonal penicillin plus beta-lactamase inhibitor. Inhibits biosynthesis of cell wall mucopeptide and is effective during active multiplication stage.
Adult Dose3.375 g IV q6h; adjust dose for renal insufficiency
Pediatric DoseNot recommended
ContraindicationsDocumented hypersensitivity; severe pneumonia, bacteremia, pericarditis, emphysema, meningitis and purulent or septic arthritis should not be treated with a PO penicillin during the acute stage
InteractionsTetracyclines may decrease effects of piperacillin; high concentrations of piperacillin may physically inactivate aminoglycosides if administered in same IV line; effects when administered concurrently with aminoglycosides are synergistic; probenecid may increase penicillin levels; high-dose parenteral penicillins may result in increased risk of bleeding
PregnancyB-Usually safe but benefits must outweigh the risks
PrecautionsPerform CBC counts prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during therapy; exercise caution in patients with hepatic insufficiencies; perform urinalysis and determine BUN and creatinine levels during therapy and adjust dose if values become elevated; monitor blood levels to avoid possible neurotoxic reactions


Drug NameTicarcillin and clavulanate (Timentin) -- Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active growth. Antipseudomonal penicillin plus beta-lactamase inhibitor that provides coverage against most gram-positive organisms, most gram-negative organisms, and most anaerobes.
Adult Dose3.1 g IV q4-6h; adjust dose for renal insufficiency
Pediatric Dose50 mg/kg, not to exceed 3.1 g IV q4-6h; adjust dose for renal insufficiency
ContraindicationsDocumented hypersensitivity; patients with severe pneumonia, bacteremia, pericarditis, emphysema, meningitis, and purulent or septic arthritis should not be treated with PO penicillin during acute stage
InteractionsTetracyclines may decrease effects of ticarcillin; high concentrations of ticarcillin may physically inactivate aminoglycosides if administered in same IV line; effects when administered concurrently with aminoglycosides are synergistic; probenecid may increase penicillin levels
PregnancyB-Usually safe but benefits must outweigh the risks
PrecautionsPerform CBC counts prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during therapy; exercise caution in patients with hepatic insufficiencies; perform urinalysis and determine BUN and creatinine levels during therapy and adjust dose if values become elevated; monitor blood levels to avoid possible neurotoxic reactions


Drug NameNafcillin (Nafcil, Nallpen, Unipen) -- Initial therapy for suspected penicillin G–resistant streptococcal or staphylococcal infections.
Use parenteral therapy initially in severe infections. Change to PO therapy as condition warrants.
Because of thrombophlebitis, particularly in the elderly, administer parenterally only for short term (1-2 d); change to PO route as clinically indicated.
Adult Dose1-2 g IV q4h; excreted through liver, so dose adjustment not necessary in renal insufficiency
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity
InteractionsAssociated with warfarin resistance when administered concurrently; effects may decrease with bacteriostatic action of tetracycline derivatives
PregnancyB-Usually safe but benefits must outweigh the risks
PrecautionsPerform CBC counts prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during therapy; exercise caution in patients with hepatic insufficiencies; perform urinalysis and determine BUN and creatinine levels during therapy and adjust dose if values become elevated; monitor blood levels to avoid possible neurotoxic reactions


Drug NameCeftazidime (Fortaz) -- Third-generation cephalosporin with broad-spectrum, gram-negative activity, including pseudomonas; lower efficacy against gram-positive organisms; higher efficacy against resistant organisms. Arrests bacterial growth by binding to one or more penicillin-binding proteins, which, in turn, inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall synthesis, thus inhibiting cell wall biosynthesis. The condition of the patient, severity of the infection, and susceptibility of the microorganism should determine the proper dose and route of administration.
Adult Dose1-2 g IV/IM q8-12h; adjust dose for renal insufficiency
Pediatric Dose30-50 mg/kg IV q8h; adjust dose for renal insufficiency
ContraindicationsDocumented hypersensitivity
InteractionsNephrotoxicity may increase with aminoglycosides, furosemide, and ethacrynic acid; probenecid may increase ceftazidime levels
PregnancyB-Usually safe but benefits must outweigh the risks
PrecautionsAdjust dose in patients with severe renal insufficiency (high doses may cause CNS toxicity); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy


Drug NameCefepime (Maxipime) -- Fourth-generation cephalosporin. Gram-negative coverage comparable to that of ceftazidime but has better gram-positive coverage (comparable to ceftriaxone). Cefepime is a zwitter ion; rapidly penetrates gram-negative cells. Best beta-lactam drug for IM administration. Poor capacity to cross blood-brain barrier precludes use for treatment of meningitis.
Adult Dose2 g IV q12h; adjust dose for renal insufficiency
Pediatric DoseNot recommended
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid may increase effects of cefepime; aminoglycosides increase the nephrotoxic potential of cefepime
PregnancyB-Usually safe but benefits must outweigh the risks
PrecautionsDosage adjustments (adult adjustments)
CrCl (mL/min) 80-50: 0.5-2 g q12-24h
CrCl 50-10: 0.5-2 g/d
CrCl <10: 0.25-0.5 g/d
HD: as for CrCl <10, with an extra 0.25 g after HD
During peritoneal dialysis: 1-2 g q48h
High doses may cause CNS toxicity; prolonged use of cefepime may predispose patients to superinfection


Drug NameCiprofloxacin (Cipro) -- Fluoroquinolone that inhibits bacterial DNA synthesis and, consequently, growth by inhibiting DNA gyrase and topoisomerases, which are required for replication, transcription, and translation of genetic material. Quinolones have broad activity against gram-positive and gram-negative aerobic organisms. Has no activity against anaerobes. Continue treatment for at least 2 d (7-14 d typical) after signs and symptoms have disappeared.
Adult Dose400 mg IV q12h; 500 mg PO q12h; adjust dose for renal insufficiency
Pediatric DoseNot recommended
ContraindicationsDocumented hypersensitivity
InteractionsAntacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after administering fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; ciprofloxacin reduces therapeutic effects of phenytoin; probenecid may increase ciprofloxacin serum concentrations;
May increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT)
PregnancyC-Safety for use during pregnancy has not been established
PrecautionsDosage adjustments (adult adjustments)
CrCl (mL/min) <10: 50% of PO or IV dose q12h
HD: 0.25-0.5 g PO or 0.2-0.4 g IV q12h
During peritoneal dialysis: 0.25-0.5 g PO or 0.2-0.4 g IV q8h
In prolonged therapy, periodically evaluate organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in patients with renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy
Not drug of first choice in pediatrics because of increased incidence of adverse events compared with controls, including arthropathy; no data exist for dose for pediatric patients with renal impairment (ie, CrCl <50 mL/min)


Drug NameLevofloxacin (Levaquin) -- For pseudomonal infections and infections due to multidrug-resistant gram-negative organisms.
Adult Dose250-500 mg/d IV/PO; adjust dose for renal insufficiency
Pediatric DoseNot recommended
ContraindicationsDocumented hypersensitivity
InteractionsAntacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; levofloxacin reduces therapeutic effects of phenytoin; probenecid may increase levofloxacin serum concentrations
May increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT)
PregnancyC-Safety for use during pregnancy has not been established
PrecautionsIn prolonged therapy, periodically evaluate organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in patients with renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy


Drug NameGentamicin (Garamycin) -- Aminoglycoside antibiotic for gram-negative coverage bacteria including Pseudomonas species. Synergistic drug with beta-lactamase against enterococci. Interferes with bacterial protein synthesis by binding to 30S and 50S ribosomal subunits.
Dosing regimens are numerous and are adjusted based on CrCl and changes in volume of distribution, as well as body space into which agent needs to distribute. Dose of gentamicin may be given IV/IM. Each regimen must be followed by at least trough level drawn on third or fourth dose, 0.5 h before dosing; may draw peak level 0.5 h after 30-min infusion.
Adult DoseLoading dose 2 mg/kg followed by 1.7 mg/kg IV/IM q8h; adjust dose for patients with renal insufficiency; further adjustments should be based on serum levels
Pediatric Dose2-2.5 mg/kg IV/IM q8h; adjust dose for renal insufficiency
Peak: 20-35 mcg/mL
Trough: <2 mcg/mL
ContraindicationsDocumented hypersensitivity; non–dialysis-dependent renal insufficiency
InteractionsCoadministration with other aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; because aminoglycosides enhance effects of neuromuscular blocking agents, prolonged respiratory depression may occur; coadministration with loop diuretics may increase auditory toxicity of aminoglycosides; possible irreversible hearing loss of varying degrees may occur (monitor regularly)
PregnancyD-Unsafe in pregnancy
PrecautionsNarrow therapeutic index (not intended for long-term therapy); caution in patients with renal failure (not on dialysis), myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment


Drug NameAmikacin (Amikin) -- Irreversibly binds to 30S subunit of bacterial ribosomes; blocks recognition step in protein synthesis; causes growth inhibition. For gram-negative bacterial coverage of infections resistant to gentamicin and tobramycin. Effective against Pseudomonas aeruginosa.
Use patient's IBW for dosage calculation. The same principles of drug monitoring for gentamicin apply to amikacin.
Adult Dose7.5 mg/kg IV/IM q8h; adjust dose for renal insufficiency; further adjustments should be based on serum levels
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with other aminoglycosides, penicillins, cephalosporins, and amphotericin B increases nephrotoxicity; enhances effects of neuromuscular blocking agents; causes respiratory depression; irreversible hearing loss may occur with coadministration of loop diuretics
PregnancyD-Unsafe in pregnancy
PrecautionsNot intended for long-term therapy; caution in patients with renal failure (not on dialysis), hypocalcemia, myasthenia gravis, and conditions that depress neuromuscular transmission


Drug NameTobramycin (Nebcin) -- Aminoglycoside antibiotic for gram-negative coverage. Used in combination with both an agent against gram-positive organisms and one that covers anaerobes.
Adult DoseLoading dose 2 mg/kg followed by 1.7 mg/kg IV/IM q8h; adjust dose for patients with renal insufficiency; further adjustments should be based on serum levels
Pediatric Dose2-2.5 mg/kg IV/IM q8h; adjust dose for renal insufficiency
Peak: 5-10 mcg/mL
Trough: <2 mcg/mL
ContraindicationsDocumented hypersensitivity
InteractionsIncreases effects of neuromuscular blockers and potentiates effect of extended-spectrum penicillins; concurrent administration with amphotericin B, cephalosporins, and loop diuretics increases risk of nephrotoxicity
PregnancyD-Unsafe in pregnancy
PrecautionsCaution in patients with renal impairment, preexisting auditory or vestibular impairment, and neuromuscular disorders; aminoglycosides are associated with nephrotoxicity and ototoxicity

Duration of therapy is not well defined. Continue parenteral antibiotics for at least 24-48 hours after patient symptoms clinically improve and the fever resolves. Then, administer a suitable oral agent and continue for an additional 2-4 weeks, as determined by complete clinical and radiographic resolution of the intrarenal process.

Predisposing factors for patients in whom antibiotic therapy fails include elderly age, diabetes mellitus, large abscesses, obstructive uropathy, and urosepsis.

Antimicrobial therapy alone does not cure patients with xanthogranulomatous pyelonephritis (XGP). Nephrectomy is required.

Surgical therapy

Historically, surgical debridement, drainage, and nephrectomy were widely used to treat corticomedullary abscesses. With the advent of effective antibiotics along with percutaneous techniques, the open surgical approach is now reserved for more severe, refractory cases.

Abscess drainage

Generally, large intrarenal abscesses require drainage if the patient has persistent fever and absence of clinical improvement after 1 week of appropriate antimicrobial therapy. Renal abscesses may be drained percutaneously under CT or ultrasonographic guidance. If perirenal abscess or infected urinoma is present, also place a percutaneous perirenal drain.

Leave the drainage tube in place until the patient is afebrile and stable. Leave the drain in situ until the output from the drain becomes minimal.

If the patient requires open surgical drainage, proceed with exploration and drainage. Irrigate the infected renal fossa copiously with antibiotic irrigant and leave perirenal drains. Reserve nephrectomy for patients with diffusely damaged renal parenchyma or patients who are septic and require urgent intervention for survival.

Nephrectomy is often required for patients with symptomatic XGP. Following nephrectomy, prognosis is excellent in patients without other urinary tract pathology.

Nephrectomy

Simple nephrectomy often suffices.

Partial nephrectomy may be possible in patients with focal disease confined to the kidney (stage I) or perinephric fat (stage II); however, the more common presentation is diffuse disease involving most of the kidney and extending to the perirenal fat (stage II) and beyond (stage III).

The xanthogranulomatous process does not recur after excision.

Preoperative details

Conduct a thorough workup that involves screening for risk factors that predispose patients to intrarenal abscess. Perform preoperative imaging to define the extent of the parenchymal process. Contrast CT scanning is the standard imaging and allows greatest definition of patient anatomy, degree of abscess extension, and associated conditions (eg, obstructive uropathy). Moreover, if surgical intervention is necessary, CT imaging helps the surgeon dictate the surgical approach.

Intraoperative details

Either supine or flank positions may be used. Usually, the flank position is preferred because of ease of establishing a drainage tract and avoiding possible peritoneal exposure to infected material. If possible, remain extraperitoneal.

Postoperative details

Administer postoperative antibiotic therapy parenterally following surgery and then convert to oral administration when patient is eating.

Antibiotic therapy is generally continued for at least 2 weeks.

Discharge patients under the following conditions:

  • Tolerating diet
  • Ambulating
  • Afebrile
  • Adequate pain control on oral analgesics

Follow-up

  • Instruct the patient to return to the clinic in 1-2 weeks for follow-up examination.
  • Check wound for signs of surgical site infection.
  • Remove staples or sutures.
  • Obtain a follow-up contrast CT scan to ensure resolution of renal parenchymal abnormalities.
  • Following surgery, inform the patient that normal activities can resume in 4-6 weeks.

For excellent patient education resources, visit eMedicine's Infections Center and Kidneys and Urinary System Center. Also, see eMedicine's patient education articles Urinary Tract Infections and Antibiotics.



The most feared complication of corticomedullary abscess is potential extension of the abscess through the renal capsule, resulting in a perinephric abscess. Gerota fascia usually contains the abscess within the perinephric space, but the process may extend into the retroperitoneum to infect adjacent structures. In these situations, simple nephrectomy is quite challenging because adjacent organs, such as the pancreas and bowel, may be involved.



Acute focal bacterial nephritis usually responds to antimicrobial therapy alone. Follow-up radiographic studies typically show complete resolution of the intrarenal lesion.

Conversely, patients with acute multifocal bacterial nephritis take longer to improve with antibiotics alone. Occasionally, patients may require some form of a drainage procedure.

In most situations, patients with large abscesses or xanthogranulomatous disease who require open surgical procedure fully recover, albeit with a higher degree of morbidity.

Prognosis improves with early recognition of symptoms and early aggressive therapy. Poor prognosis factors include patients who are elderly and patients with urosepsis, anatomic abnormalities, advanced disease, and impaired renal function at presentation.



  • Less invasive operative techniques (eg, laparoscopic nephrectomy)
  • Continued improvements in antibiotics against pathogens that cause corticomedullary abscess



Media file 1:  Contrasted CT scan that demonstrates a corticomedullary abscess in a 27-year-old patient with diabetes mellitus who has a history of multiple urinary tract infections. Note the heterogeneous hypodense lesion in the right kidney. Extracapsular extension is not present.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  CT



  • Abdul-Halim H, Kehinde EO, Abdeen S, et al. Severe emphysematous pyelonephritis in diabetic patients: diagnosis and aspects of surgical management. Urol Int. 2005;75(2):123-8. [Medline].
  • Alan C, Ataus S, Tunc B. Xanthogranulamatous pyelonephritis with psoas abscess: 2 cases and review of the literature. Int Urol Nephrol. 2004;36(4):489-93. [Medline].
  • Anderson KA, McAninch JW. Renal abscesses: classification and review of 40 cases. Urology. Oct 1980;16(4):333-8. [Medline].
  • Brook I. Urinary tract and genito-urinary suppurative infections due to anaerobic bacteria. Int J Urol. Mar 2004;11(3):133-41. [Medline].
  • Chen J, Koontz WW. Inflammatory lesions of the kidney. AUA Update Series. 1995;XIV(26):210-216.
  • Claes H, Vereecken R, Oyen R, et al. Xanthogranulomatous pyelonephritis with emphasis on computerized tomography scan. Retrospective study of 20 cases and literature review. Urology. Apr 1987;29(4):389-93. [Medline].
  • Corriere JN Jr, Sandler CM. The diagnosis and immediate therapy of acute renal and perirenal infections. Urol Clin North Am. Jun 1982;9(2):219-28. [Medline].
  • Dalla Palma L, Pozzi-Mucelli F, Ene V. Medical treatment of renal and perirenal abscesses: CT evaluation. Clin Radiol. Dec 1999;54(12):792-7. [Medline].
  • Dembry LM, Andriole VT. Renal and perirenal abscesses. Infect Dis Clin North Am. Sep 1997;11(3):663-80. [Medline].
  • Dembry, LM. Renal and perirenal abscesses. Curr Treat Options Infect Dis. 2002;4:21-30.
  • Forland M, Thomas V, Shelokov A. Urinary tract infections in patients with diabetes mellitus. Studies on antibody coating of bacteria. JAMA. Oct 31 1977;238(18):1924-6. [Medline].
  • Huisman TK, Sands JP. Focal xanthogranulomatous pyelonephritis associated with renal cell carcinoma. Urology. Mar 1992;39(3):281-4. [Medline].
  • Kawashima A, Sandler CM, Ernst RD, et al. Renal inflammatory disease: the current role of CT. Crit Rev Diagn Imaging. Oct 1997;38(5):369-415. [Medline].
  • Malek RS, Elder JS. Xanthogranulomatous pyelonephritis: a critical analysis of 26 cases and of the literature. J Urol. May 1978;119(5):589-93. [Medline].
  • Meares EM. Nonspecific infections of the genitourinary tract. In: Tanagho EA, McAnich JW, eds. Smith's General Urology. New York, NY:. McGraw-Hill;1995:201-44.
  • Medical Economics Company. Physician's Desk Reference. 54th ed. 2000.
  • Olazabal A, Velasco M, Martinez A, et al. Emphysematous pyelonephritis. Urology. Jan 1987;29(1):95-8. [Medline].
  • Patel NP, Lavengood RW, Fernandes M, et al. Gas-forming infections in genitourinary tract. Urology. Apr 1992;39(4):341-5. [Medline].
  • Patterson JE, Andriole VT. Bacterial urinary tract infections in diabetes. Infect Dis Clin North Am. Sep 1997;11(3):735-50. [Medline].
  • Petronic V, Buturovic J, Isvaneski M. Xanthogranulomatous pyelonephritis. Br J Urol. Oct 1989;64(4):336-8. [Medline].
  • Rinder MR. Renal abscess: an illustrative case and review of the literature. Md Med J. Oct 1996;45(10):839-43. [Medline].
  • Roberts JA. Pyelonephritis, cortical abscess, and perinephric abscess. Urol Clin North Am. Nov 1986;13(4):637-45. [Medline].
  • Roberts JA. Management of pyelonephritis and upper urinary tract infections. Urol Clin North Am. Nov 1999;26(4):753-63. [Medline].
  • Rubenstein JN, Schaeffer AJ. Managing complicated urinary tract infections: the urologic view. Infect Dis Clin North Am. Jun 2003;17(2):333-51. [Medline].
  • Schaeffer AJ. Infections of the urinary tract. In: Campbell MF, Retik AB, eds. Campbell's Urology. 7th ed. Philadelphia, Pa:. WB Saunders and Co;1998:533-614.
  • Stamm WE, Hooton TM, Johnson JR, et al. Urinary tract infections: from pathogenesis to treatment. J Infect Dis. Mar 1989;159(3):400-6. [Medline].
  • Yen DH, Hu SC, Tsai J, et al. Renal abscess: early diagnosis and treatment. Am J Emerg Med. Mar 1999;17(2):192-7. [Medline].

Renal Corticomedullary Abscess excerpt

Article Last Updated: Nov 19, 2005